Fierce Health Payer September 16, 2021
Robert King

A collection of venture capital funds that invest in pharma and biotech startups issued a dire warning that funding for new drugs will dry up if Democrats move forward with giving Medicare the power to negotiate drug prices for certain drugs and extend those prices to commercial plans.

“Investments won’t just be reduced, it will drop off a cliff,” said John Stanford, executive director of venture capital coalition Incubate, during the briefing Wednesday in Washington, D.C.

The briefing is the latest escalating rhetoric from the pharmaceutical industry as Democrats aim to include broad Medicare drug price negotiation powers in a $3.5 trillion infrastructure package expected to be voted on this fall. Venture firms said that giving Medicare broad authority to negotiate lower...

Today's Sponsors


Today's Sponsors

Crossover Health

Today's Sponsor

Institute for Healthcare Improvement

Topics: Biotechnology, Congress / White House, Govt Agencies, Investments, Pharma, Pharma / Biotech, Regulations, Trends
Xilio, Ventyx IPOs raise $269M to fuel plans to compete with big pharma drugs
AION Labs, Biotech Innovation Lab Launched by Top Pharma, Tech and Investment Leaders
Dice’s IPO roll comes up with $204M for R&D of oral drugs to rival biologics
Why Pharma Must Invest in Key Account Management Capabilities
Erasca’s IPO leads the way as three cancer biotechs raise $534M for clinical trials